Biotech Stocks Facing FDA Decision In November 2025

Several biotech firms face critical FDA approval decisions in November 2025 for novel therapies, representing significant catalysts. Arrowhead Pharmaceuticals (ARWR) awaits a November 18 verdict on Plozasiran for familial chylomicronemia syndrome. By November 28, Otsuka Holdings (OTSKF) expects a decision on Sibeprenlimab for IgA nephropathy, which analysts project as a potential blockbuster, while Bayer (BAYRY) awaits approval for Sevabertinib for advanced HER2-mutated NSCLC. Ascendis Pharma (ASND) has a November 30 decision for Navepegritide for achondroplasia, and Kura Oncology (KURA) also anticipates a November 30 ruling for Ziftomenib, a potential first-in-class therapy for NPM1-mutant relapsed/refractory AML with an estimated U.S. market opportunity of $350-400 million annually.

Analysis

November 2025 marks a critical period for several biotech firms awaiting FDA approval decisions for novel therapies, with the agency having approved 34 novel drugs year-to-date compared to 38 in the same period last year. These upcoming verdicts represent significant near-term catalysts for Arrowhead Pharmaceuticals, Otsuka Holdings, Bayer, Ascendis Pharma, and Kura Oncology. The overall market sentiment surrounding these approvals is strongly positive, indicating high expectations for successful outcomes.

Otsuka Holdings' Sibeprenlimab for IgA nephropathy and Kura Oncology's Ziftomenib for NPM1-mutant relapsed/refractory AML stand out with the highest positive sentiment scores (0.8 and 0.9 respectively). Sibeprenlimab is projected by analysts to be a potential blockbuster due to its novel mechanism, while Ziftomenib, if approved, would be a first-in-class therapy addressing a $350-400 million annual U.S. market opportunity with no current FDA-approved alternatives.

Arrowhead Pharma's Plozasiran for familial chylomicronemia syndrome and Ascendis Pharma's Navepegritide for achondroplasia face existing competition from Ioni's Pharma's Tryngolza ($26M H1 2025 sales) and BioMarin's Voxzogo ($221M Q2 2025 revenue), respectively. Bayer's Sevabertinib for advanced NSCLC would also enter a market with established treatments like Enhertu and Hernexeos, positioning it as an additional option rather than a first-in-class. The success of these therapies will depend on demonstrating superior efficacy or convenience.

Key Decisions for Investors

• Investors should closely monitor the specific FDA decision dates in November 2025 for ARWR, OTSKF, BAYRY, ASND, and KURA, as approval or rejection will significantly impact their stock performance.
• Prioritize companies like Kura Oncology and Otsuka Holdings with high-potential, first-in-class, or blockbuster-projected drugs that address unmet needs or offer significant advantages over existing therapies.
• For drugs entering markets with established competitors (e.g., ARWR, ASND, BAYRY), investors should analyze the potential for market share capture based on clinical profile, pricing, and commercial strategy.
• While high sentiment for OTSKF and KURA suggests strong upside potential, investors should also factor in the inherent binary risk associated with regulatory decisions.